6-K 1 gsk201507016k2.htm DIRECTOR/PDMR SHAREHOLDING gsk201507016k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending July 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
------
 
 
GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
 
I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').
 
On 30 June 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £13.45 per Ordinary Share, and notional ADSs at a price of $42.20 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2015 to 30 June 2015:
 
Non Executive Director
Ordinary Shares
No. of ADSs
Sir Philip Hampton
2,730.912
 
Professor Sir Roy Anderson
673.792
 
Dr Stephanie Burns
 
539.199
Stacey Cartwright
534.387
 
Lynn Elsenhans
 
1,070.720
Judy Lewent
 
457.147
Sir Deryck Maughan
 
1,359.719
Dr Daniel Podolsky
 
1,019.789
Urs Rohner
589.536
 
Hans Wijers
534.387
 
     
 
The Company and the Non-Executive Directors were informed of these allocations on 1 July 2015.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
 
 
V A Whyte
Company Secretary
 
1 July 2015


 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: July 01, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc